They are classified as glucagon-like peptide 1 (GLP-1) agonists and, in addition to diabetes treatment, also demonstrate other benefits including weight loss and protective heart-health effects.While ...

The phase 3 trial success over Lilly’s Trulicity (dulaglutide), an already-marketed GLP-1 class rival, further bolsters semaglutide's profile ahead of its anticipated approval later this year as ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...